View in EDS HTML Full Text PDF Full Text

IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials.

Saved in:
Bibliographic Details
Title: IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials.
Authors: Steplewski K; GSK, Collegeville, PA, USA.; BridgeBio Inc., San Francisco, CA, USA., Walker L; GSK HQ, 79 New Oxford Street, London, UK., Coffee N; Sanofi, 450 Water Street, Cambridge, MA, 02141, USA. Nefeteria.Coffee@sanofi.com., Fallon M; Daiichi Sankyo UK Ltd., Uxbridge, UK., Yonemochi R; Daiichi Sankyo (China) Holdings Co., LTD, Shanghai, China., Alpers D; Washington University School of Medicine, St Louis, MO, USA., Rockey D; Digestive Disease Research Center, Charleston, SC, USA., Lewis J; Division of Gastroenterology, Georgetown University, Washington, DC, USA., Cohen E; Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, IL, USA., Caminis J; Gilead Oncology, Patient Safety, US Parsippany, Parsippany, NJ, USA., Hey-Hadavi J; Pfizer, New York, NY, USA., Andrade RJ; Gastroenterology Service, University Hospital-IBIMA, CIBERehd, Málaga, Spain., Palmer M; Liver Consulting LLC New York, New York, NY, USA.
Source: Drug safety [Drug Saf] 2025 Aug; Vol. 48 (8), pp. 855-874. Date of Electronic Publication: 2025 Apr 03.
Publication Type: Consensus Statement; Journal Article
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9002928 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1942 (Electronic) Linking ISSN: 01145916 NLM ISO Abbreviation: Drug Saf Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40178787
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Steplewski+K%22">Steplewski K</searchLink>; GSK, Collegeville, PA, USA.; BridgeBio Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Walker+L%22">Walker L</searchLink>; GSK HQ, 79 New Oxford Street, London, UK.<br /><searchLink fieldCode="AU" term="%22Coffee+N%22">Coffee N</searchLink>; Sanofi, 450 Water Street, Cambridge, MA, 02141, USA. Nefeteria.Coffee@sanofi.com.<br /><searchLink fieldCode="AU" term="%22Fallon+M%22">Fallon M</searchLink>; Daiichi Sankyo UK Ltd., Uxbridge, UK.<br /><searchLink fieldCode="AU" term="%22Yonemochi+R%22">Yonemochi R</searchLink>; Daiichi Sankyo (China) Holdings Co., LTD, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Alpers+D%22">Alpers D</searchLink>; Washington University School of Medicine, St Louis, MO, USA.<br /><searchLink fieldCode="AU" term="%22Rockey+D%22">Rockey D</searchLink>; Digestive Disease Research Center, Charleston, SC, USA.<br /><searchLink fieldCode="AU" term="%22Lewis+J%22">Lewis J</searchLink>; Division of Gastroenterology, Georgetown University, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+E%22">Cohen E</searchLink>; Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Caminis+J%22">Caminis J</searchLink>; Gilead Oncology, Patient Safety, US Parsippany, Parsippany, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Hey-Hadavi+J%22">Hey-Hadavi J</searchLink>; Pfizer, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Andrade+RJ%22">Andrade RJ</searchLink>; Gastroenterology Service, University Hospital-IBIMA, CIBERehd, Málaga, Spain.<br /><searchLink fieldCode="AU" term="%22Palmer+M%22">Palmer M</searchLink>; Liver Consulting LLC New York, New York, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229002928%22">Drug safety</searchLink> [Drug Saf] 2025 Aug; Vol. 48 (8), pp. 855-874. <i>Date of Electronic Publication: </i>2025 Apr 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Consensus Statement; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>9002928 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1942 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201145916%22">01145916 </searchLink><i>NLM ISO Abbreviation: </i>Drug Saf <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40178787
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40264-025-01540-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 855
    Titles:
      – TitleFull: IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Steplewski K
      – PersonEntity:
          Name:
            NameFull: Walker L
      – PersonEntity:
          Name:
            NameFull: Coffee N
      – PersonEntity:
          Name:
            NameFull: Fallon M
      – PersonEntity:
          Name:
            NameFull: Yonemochi R
      – PersonEntity:
          Name:
            NameFull: Alpers D
      – PersonEntity:
          Name:
            NameFull: Rockey D
      – PersonEntity:
          Name:
            NameFull: Lewis J
      – PersonEntity:
          Name:
            NameFull: Cohen E
      – PersonEntity:
          Name:
            NameFull: Caminis J
      – PersonEntity:
          Name:
            NameFull: Hey-Hadavi J
      – PersonEntity:
          Name:
            NameFull: Andrade RJ
      – PersonEntity:
          Name:
            NameFull: Palmer M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2025 Aug
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1179-1942
          Numbering:
            – Type: volume
              Value: 48
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Drug safety
              Type: main
ResultId 1